Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 462-466

  Bachmann, Christian J ^a   Rieger Gies, Anette ^b   Heinzel Gutenbrunner, Monika ^a   Hiemke, Christoph ^b   Remschmidt, Helmut ^a   Theisen, Frank M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIPERIDEN; CLOZAPINE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; PIRENZEPINE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; MALE; MENTAL HEALTH CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; STEADY STATE; AGING; BIOTRANSFORMATION; BLOOD; DOSE RESPONSE; DRUG MONITORING; METABOLISM; REGRESSION ANALYSIS; SEXUAL DEVELOPMENT;

ADOLESCENT; ADULT; AGING; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 58149132158     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318178e18d     Document Type: Article

References (23)

1. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole: A novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
2. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10:317-336.
3. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-187.
4. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify® (aripiprazole) tablets prescribing information. Available at: www.abilify.com. Accessed September 13, 2007.
5. Fleischhacker WW. Aripiprazole. ExpOpin Pharmacother. 2005;6:2091-2101.
6. Swainston Harrison T, Perry CM. Aripiprazole. A review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736.
7. Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:593-600.
8. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10:141-148.
9. Findling RL, Blumer JL, Kauffman R, et al. Aripiprazole in pediatric conduct disorder: a pilot study. Eur Neuropsychopharmacol. 2003; 12(Suppl 4):S335.
10. Oren DA. Aripiprazole in pediatric conduct disorder: a pilot study. Poster 234, presented at the 55th Institute on Psychiatric Services, American Psychiatric Association, Boston, MA, October 29-November 2, 2003.
11. Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68:1088-1093.
12. Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007;40:72-76.
13. Kirschbaum KM, Müller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem. 2005;51:1718-1721.
14. Zuo X, Liu S, Yi Z, et al. Steady-state pharmacokinetic properties of aripiprazole 10 mg po q12h in Han Chinese adults with schizophrenia: a prospective, open-label, pilot study. Curr Ther Res Clin Exp. 2006;67: 258-269.
15. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28:744-749.
16. Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. May 11, 2007 [Epub ahead of print].
17. Auby P, Saha A, Ali M, et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Eur Neuropsychopharmacol. 2002;12(Suppl 3): S288.
18. Bachmann C, de Lange D, Nicksch B, et al. Repeated creatine kinase elevation under treatment with quetiapine, clozapine and aripiprazole in an adolescent. J Clin Psychopharmacol. 2007;27:710-711.
19. Bachmann C, Haberhausen M, Heinzel-Gutenbrunner M, et al. Large intraindividual variability of olanzapine serum concentrations in adolescents. Ther Drug Monit. 2008;30:108-112.
20. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, metabolism and excretion of xenobiotics between the paediatric and adult populations. Exp Opin Drug Metab Toxicol. 2005;1:447-471.
21. Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, gender, smoking, and comedication. Ther Drug Monit. 2006;28:750-759.
22. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 2007;40:107-110.
23. Mallikaarjun S, Ali MW, Salazar DE, et al. The effects of age and gender on the pharmacokinetics of aripiprazole. Clin Pharmacol Ther. 2002;71:P66.